106 related articles for article (PubMed ID: 3861748)
1. Preparation for hapten help by glucan, muramyl dipeptide, and its L-ala-Glycerol-mycolate derivative.
Leech SH; Di Luzio NR; Leclerc C
J Leukoc Biol; 1985 Aug; 38(2):317-25. PubMed ID: 3861748
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of the in vivo dinitrophenyl antibody response to the DNP conjugate of L-glutamic acid60-L-alanine30-L-Tyrosine10 (GAT) polymer by a synthetic adjuvant, muramyl dipeptide (MDP): target cells for adjuvant activity and isotypic pattern of MDP-stimulated response.
Lowy I; Theze J; Chedid L
J Immunol; 1980 Jan; 124(1):100-4. PubMed ID: 6965289
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs.
Parant MA; Audibert FM; Chedid LA; Level MR; Lefrancier PL; Choay JP; Lederer E
Infect Immun; 1980 Mar; 27(3):826-31. PubMed ID: 7380554
[TBL] [Abstract][Full Text] [Related]
4. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.
Shima J; Yoshioka T; Nakajima H; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1988; 26(1):43-7. PubMed ID: 2964268
[TBL] [Abstract][Full Text] [Related]
5. Marked enhancement in vivo of adjuvant activity of muramyl dipeptide to protein antigens and to synthetic weak immunogens with monoclonal anti-muramyl dipeptide antibodies.
Bahr GM; Tello DS; Chedid LA
Infect Immun; 1985 Aug; 49(2):312-9. PubMed ID: 4018873
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the antigenic relationship of various derivatives of n-acetyl-muramyl-l-ala-d-isoglutamine (MDP), using anti-MDP antibodies.
Bahr GM; Carelli C; Audibert F; Modabber F; Chedid L
Mol Immunol; 1982 May; 19(5):737-45. PubMed ID: 7110143
[TBL] [Abstract][Full Text] [Related]
7. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.
Sano H; Kosugi A; Sano S; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1987; 25(3):180-4. PubMed ID: 2960447
[TBL] [Abstract][Full Text] [Related]
8. Hapten-specific T cell response to azobenzene-arsonate-N-acetyl-L-tyrosine (ABA-tyr) in Lewis rats. II. Induction and suppression of ABA-specific helper cell activity for antibody production.
Miyagawa N; Lawn CY; Leskowitz S
Microbiol Immunol; 1982; 26(9):853-69. PubMed ID: 6218379
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of the proliferative response of thymocytes to phytohemagglutinin by the muramyl dipeptide1.
Iribe H; Koga T
Cell Immunol; 1984 Oct; 88(1):9-15. PubMed ID: 6332683
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of carrier-specific helper T cell function by the synthetic adjuvant, N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP).
Sugimoto M; Germain RN; Chedid L; Benacerraf B
J Immunol; 1978 Mar; 120(3):980-2. PubMed ID: 344799
[TBL] [Abstract][Full Text] [Related]
11. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity.
Hamaoka T; Takai Y; Kosugi A; Mizushima Y; Shima J; Kusama T; Fujiwara H
Cancer Immunol Immunother; 1985; 20(3):183-8. PubMed ID: 2933141
[TBL] [Abstract][Full Text] [Related]
12. Study of immunomodulatory properties of N-acetylmuramyl-L-alanyl-D-isoglutamine and N-acetylglucosaminyl-(beta 1----4)-N-acetylmuramyl-L-alanyl-D-isoglutamine.
Dozmorov IM; Kuzin II; Lutsan NI; Lutsenko GV; Prokhorova AL; Sapozhnikov AM; Andronova TM; Ivanov VT
Biomed Sci; 1991; 2(6):651-8. PubMed ID: 1841635
[TBL] [Abstract][Full Text] [Related]
13. The muramyl dipeptide analog GMTP-N-DPG preferentially induces cellular immunity to soluble antigens.
Fast DJ; Vosika GJ
Vaccine; 1997 Nov; 15(16):1748-52. PubMed ID: 9364678
[TBL] [Abstract][Full Text] [Related]
14. Comparison of immunomodulatory activities in mice and guinea pigs of a synthetic desmuramyl peptidolipid triglymyc.
Leclerc CD; Audibert FM; Chedid LA; Deriaud EJ; Masihi NK; Lederer E
Infect Immun; 1984 Mar; 43(3):870-5. PubMed ID: 6698611
[TBL] [Abstract][Full Text] [Related]
15. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. I. Effect on the antibody response to bovine serum albumin and sheep red blood cells of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin.
Bomford R
Clin Exp Immunol; 1980 Feb; 39(2):426-34. PubMed ID: 6248282
[TBL] [Abstract][Full Text] [Related]
16. Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.
Heymer B; Finger H; Wirsing CH
Z Immunitatsforsch Immunobiol; 1978 Oct; 155(1):87-92. PubMed ID: 706536
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of the antibody response by hapten help. II. Determination by many genes outside the MHC.
Leech SH; Bryan CF; Elston RC
J Immunogenet; 1985; 12(4-5):229-38. PubMed ID: 2939150
[TBL] [Abstract][Full Text] [Related]
18. Control of IgE responses. V. Oral administration of a synthetic derivative of the inner bacterial cell wall (SDZ 280.636) to sensitized mice induces isotype specific suppression of peak hapten specific IgE antibody forming cell responses, serum IgE levels and immediate hypersensitivity responses.
Auci DL; Kleiner GI; Chice SM; Athanassiades TJ; Dukor P; Durkin HG
Immunol Invest; 1998; 27(1-2):105-20. PubMed ID: 9561922
[TBL] [Abstract][Full Text] [Related]
19. Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity.
Kosugi A; Shima J; Sano H; Ogata M; Kusama T; Fujiwara H; Hamaoka T
Infect Immun; 1986 Dec; 54(3):768-73. PubMed ID: 3491048
[TBL] [Abstract][Full Text] [Related]
20. Effects of in vivo administration of adamantylamide dipeptide on bone marrow granulocyte-macrophage hemopoietic progenitor cells (GM-CFC) and on ability of serum of the treated mice to stimulate GM-CFC colony formation in vitro: comparison with muramyl dipeptide and glucan.
Vacek A; Hofer M; Masek K
Immunopharmacol Immunotoxicol; 1999 Feb; 21(1):1-14. PubMed ID: 10084327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
